amrinone has been researched along with digoxin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 5 (21.74) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP | 1 |
| Junkin, P; Riley, CM | 1 |
| Galvao, M; Jondeau, G; Katz, SD; Klapholz, M; LeJemtel, TH; Levato, P; Maher, M | 1 |
| Uretsky, BF | 1 |
| Alderman, MH; Marantz, PR; Tobin, JN | 1 |
| Roberts, R | 1 |
| Coates, JE; LeGatt, DF | 1 |
| Ooi, DS; Perkins, SL | 1 |
| Boucek, MM; Chang, R; Synhorst, DP | 1 |
| Buser, PT; Jasmin, G; Parmley, WW; Wikman-Coffelt, J; Wu, SY | 1 |
| Joseph, G; Klaus, W; Zhao, Y | 1 |
2 review(s) available for amrinone and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Diagnostic heterogeneity in clinical trials for congestive heart failure.
Topics: Amrinone; Clinical Trials as Topic; Digoxin; Heart Failure; Humans; Hydralazine; Metoprolol; Research Design | 1988 |
1 trial(s) available for amrinone and digoxin
| Article | Year |
|---|---|
Modulation of inotropic therapy by venodilation in acute heart failure: a randomised comparison of four inotropic agents, alone and combined with isosorbide dinitrate.
Topics: Adult; Aged; Amrinone; Cardiotonic Agents; Digoxin; Dobutamine; Heart Failure; Humans; Isosorbide Dinitrate; Male; Middle Aged; Prenalterol; Prospective Studies; Single-Blind Method; Vasodilation | 1992 |
20 other study(ies) available for amrinone and digoxin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Stability of amrinone and digoxin, procainamide hydrochloride, propranolol hydrochloride, sodium bicarbonate, potassium chloride, or verapamil hydrochloride in intravenous admixtures.
Topics: Amrinone; Bicarbonates; Chromatography, High Pressure Liquid; Digoxin; Drug Combinations; Drug Incompatibility; Drug Stability; Potassium Chloride; Procainamide; Propranolol; Sodium; Sodium Bicarbonate; Verapamil | 1991 |
Control of arteriolar resistance in heart failure. Partial attenuation of specific phosphodiesterase inhibitor-mediated vasodilation by digitalis glycosides.
Topics: Aged; Aged, 80 and over; Amrinone; Arterioles; Blood Flow Velocity; Digitalis Glycosides; Digoxin; Female; Femoral Artery; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Vascular Resistance; Vasodilation | 1992 |
Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering?
Topics: Amrinone; Cardiotonic Agents; Digoxin; Dobutamine; Enoximone; Ethanolamines; Heart; Heart Failure; Heart Function Tests; Hemodynamics; Humans; Imidazoles | 1986 |
Inotropic therapy for cardiac failure associated with acute myocardial infarction.
Topics: Amrinone; Cardiotonic Agents; Digoxin; Diuretics; Dobutamine; Dopamine; Heart Failure; Humans; Myocardial Infarction; Vasodilator Agents | 1988 |
Lack of interference by therapeutic concentrations of Inocor (amrinone lactate) in the TDx assay for digoxin.
Topics: Amrinone; Digoxin; False Positive Reactions; Humans; Reagent Kits, Diagnostic | 1988 |
Inocor (amrinone lactate) interferences with TDX digoxin measurements.
Topics: Amrinone; Cross Reactions; Digoxin; False Negative Reactions; Humans | 1987 |
Hemodynamic consequences of inotropic support with digoxin or amrinone in lambs with ventricular septal defect.
Topics: Aminopyridines; Amrinone; Animals; Animals, Newborn; Digoxin; Dose-Response Relationship, Drug; Heart Septal Defects, Ventricular; Hemodynamics; Myocardial Contraction; Sheep; Time Factors | 1985 |
Distinct modulation of myocardial performance, energy metabolism, and [Ca2+]i transients by positive inotropic drugs in normal and severely failing hamster hearts.
Topics: Amrinone; Animals; Blood Pressure; Bucladesine; Calcium; Cardiomyopathies; Cardiotonic Agents; Cricetinae; Digoxin; Disease Models, Animal; Dobutamine; Energy Metabolism; Heart Failure; Isoproterenol; Magnetic Resonance Spectroscopy; Mesocricetus; Myocardial Contraction; Oxygen Consumption; Phosphates; Phosphorylation | 1995 |
[Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart].
Topics: Amrinone; Animals; Cardiotonic Agents; Coronary Circulation; Crataegus; Digoxin; Epinephrine; Guinea Pigs; Heart; Heart Rate; In Vitro Techniques; Male; Milrinone; Myocardial Contraction; Plant Extracts; Plants, Medicinal; Pyridones; Refractory Period, Electrophysiological; Vasoconstrictor Agents | 1995 |